Nevertheless, our data support the view that targeting the complement system and other inflammatory pathways poses an intriguing possibility for the treatment of aging-associated diseases and cognitive decline, which has recently been demonstrated for inhibition of NF-κB signaling in a mouse model of AD (Liu et al., 2014). Here, NFKB1 is linked to Alzheimer disease.